Montelukast combined with intranasal mometasone furoate versus intranasal mometasone furoate; a comparative study in treatment of adenoid hypertrophy
| Autor: | Abou‐bakr E. Ras, Abdelrahman Ahmed Abdelalim, Mona Hosny Hamed |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cyclopropanes
Male medicine.medical_specialty medicine.medical_treatment Mometasone furoate Mouth breathing Acetates Sulfides Adenoid Gastroenterology 03 medical and health sciences 0302 clinical medicine Recurrence Internal medicine medicine Humans Prospective Studies 030223 otorhinolaryngology Child Montelukast Administration Intranasal rhinorrhea business.industry Hypertrophy Nasal Sprays medicine.disease medicine.anatomical_structure Treatment Outcome Otorhinolaryngology Nasal spray 030220 oncology & carcinogenesis Child Preschool Adenoids Quinolines Nasal administration Drug Therapy Combination Female medicine.symptom business Adenoid hypertrophy Mometasone Furoate medicine.drug |
| Zdroj: | American journal of otolaryngology. 41(6) |
| ISSN: | 1532-818X |
| Popis: | To evaluate the role of combined therapy using montelukast and intranasal mometasone furoate compared to intranasal mometasone furoate alone in treatment of adenoid hypertrophy regarding efficacy and recurrence rate.The study included 100 children with adenoid hypertrophy, they were randomly assigned to two groups. Group I (50 patients) received combined therapy using montelukast and mometasone furoate nasal spray. Group II (50 patients) received only mometasone furoate nasal spray. Patients were treated for 3 months and observed for 3 months after stoppage of treatment. Patients were evaluated using symptoms scores, Adenoid/Nasopharyngeal ratio and endoscopic grading of adenoid hypertrophy.After 3 months of treatment, group I showed significant better scores of main symptoms than group II; (P = 0.001), (P = 0.019) and (P = 0.008) for rhinorrhea, mouth breathing and snoring respectively. The mean A/N ratio was 52.8 ± 11.3 in group I better than 62.88 ± 12.10 in group II (P 0.001). Regarding the adenoid hypertrophy grading, significant reduction in size was found in group I in 34 (68%) patients better than in group II in 18 (36%) patients (P = 0.001). After further 3 months of follow up, the mean A/N ratio was 58.46 ± 10.05 in group I better than 66.36 ± 10.46 in group II (P 0.001). Recurrence occurred in 8 (23.5%) cases out of 34 improved cases in group I better than 10 (55.5%) cases out of 18 cases in group II (P = 0.02).Combining oral montelukast with intranasal mometasone in treatment of adenoid hypertrophy provided better improvements and less recurrence in comparison with single therapy using intranasal mometasone alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect